Analytical Data
-
基因名
EREG
- Application
-
别名
EPR; ER; Proepiregulin
-
种属
Human
-
表达系统
E. coli
-
标签
N- His & GST
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O14944
-
表达区间
Val63~Leu108
-
分子量
36kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EREG (Epiregulin) is a member of the epidermal growth factor (EGF) family, which plays a crucial role in cellular processes such as proliferation, differentiation, and survival. It is expressed in various tissues and has been implicated in several physiological and pathological conditions, including cancer, wound healing, and inflammatory diseases. Recent studies emphasize the importance of EREG in tumor progression and metastasis, highlighting its potential as a therapeutic target. The research surrounding the EREG recombinant protein focuses on understanding its structure-function relationships, signaling pathways, and interactions with other growth factors and receptors. Additionally, the role of EREG in modulating the tumor microenvironment and its impact on immune responses are emerging areas of interest. Investigating the recombinant form of EREG not only aids in elucidating its biological functions but also facilitates the development of novel therapeutic strategies, such as monoclonal antibodies or inhibitors, to combat EREG-related pathologies. As we delve deeper into the mechanisms of EREG, its implications in oncology and regenerative medicine could lead to innovative approaches in treating various diseases, making it a significant target for future research and clinical applications.
